Search - tctmd.com

Displaying 921 - 940 of 980

Sort: Relevancy | Date

Presentation TCT 2012

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

Presenter: Fabio Mangiacapra

October 23, 2012

Presentation TCT 2012

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

Presenter: Michael Maeng

October 23, 2012

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Presentation TCT 2012

TCT-52. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial

Presenter: Gregg Stone

October 23, 2012

Presentation TCT 2012

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

Presenter: Renato Valenti

October 23, 2012

$TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...$

Presentation TCT 2012

TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...

Presenter: Lamin King

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

News Conference News TCT 2012

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

October 23, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

Presenter: Paul Gurbel

October 22, 2012

Presentation TCT 2012

ISAR-SAFE Update

Presenter: Adnan Kastrati

October 22, 2012

Presentation TCT 2012

How to Choose Between CABG and PCI in Complex CAD: A Practical Approach

Presenter: Gennaro Sardella

October 22, 2012

Presentation TCT 2012

Do Patient and Stent Platform Specific Variables Matter (e.g. ACS vs. Stable CAD, First vs. Second Generation DES)?

Presenter: Elvin Kedhi

October 22, 2012

Presentation TCT 2012

DAPT Trial Update

Presenter: Laura Mauri

October 22, 2012

Presentation TCT 2012

Concomitant CAD and Aortic Stenosis: Implications and Revascularization Strategies

Presenter: David Hildick-Smith

October 22, 2012

Presentation TCT 2012

Case 1: Complex CAD: CABG or PCI?

Presenter: Murat Cayli

October 22, 2012

Presentation TCT 2012

Calcified Lesions: New Insights in Stable CAD and ACS from Large-Scale Clinical Trials

Presenter: Philippe Genereux

October 22, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Presenter: Laurent Bonello

October 22, 2012

Advertisement

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

TCT-52. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

Several Trials Highlight DES Comparisons

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

ISAR-SAFE Update

How to Choose Between CABG and PCI in Complex CAD: A Practical Approach

Do Patient and Stent Platform Specific Variables Matter (e.g. ACS vs. Stable CAD, First vs. Second Generation DES)?

DAPT Trial Update

Concomitant CAD and Aortic Stenosis: Implications and Revascularization Strategies

Case 1: Complex CAD: CABG or PCI?

Calcified Lesions: New Insights in Stable CAD and ACS from Large-Scale Clinical Trials

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content